Maze Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| License revenue | $20,000 | $— |
| Operating expenses: | ||
| Research and development | 34,148 | 27,580 |
| General and administrative | 12,405 | 7,821 |
| Total operating expenses | 46,553 | 35,401 |
| Loss from operations | (26,553) | (35,401) |
| Other income (expense): | ||
| Interest and other income, net | 3,211 | 2,615 |
| Interest expense | (866) | — |
| Total other income, net | 2,345 | 2,615 |
| Net loss | $(24,208) | $(32,786) |
| Net loss per share, basic and diluted (see Note 12): | $(0.45) | $(1.15) |
| Weighted-average shares of common stock outstanding used to compute net loss per share, basic and diluted (see Note 12): | 53,897,216 | 28,628,430 |
| Comprehensive loss: | ||
| Net loss | $(24,208) | $(32,786) |
| Other comprehensive loss: | ||
| Net unrealized loss on marketable securities | (245) | — |
| Comprehensive loss | $(24,453) | $(32,786) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.